Logo image of IFRX

INFLARX NV (IFRX) Stock Fundamental Analysis

USA - NASDAQ:IFRX - NL0012661870 - Common Stock

1.47 USD
-0.11 (-6.96%)
Last: 9/11/2025, 8:00:01 PM
1.49 USD
+0.02 (+1.36%)
Pre-Market: 9/12/2025, 8:54:36 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IFRX. IFRX was compared to 541 industry peers in the Biotechnology industry. IFRX has a bad profitability rating. Also its financial health evaluation is rather negative. IFRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IFRX had negative earnings in the past year.
IFRX had a negative operating cash flow in the past year.
In the past 5 years IFRX always reported negative net income.
In the past 5 years IFRX always reported negative operating cash flow.
IFRX Yearly Net Income VS EBIT VS OCF VS FCFIFRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of IFRX (-61.67%) is comparable to the rest of the industry.
IFRX has a Return On Equity of -79.40%. This is comparable to the rest of the industry: IFRX outperforms 52.68% of its industry peers.
Industry RankSector Rank
ROA -61.67%
ROE -79.4%
ROIC N/A
ROA(3y)-41.63%
ROA(5y)-39.97%
ROE(3y)-49.99%
ROE(5y)-47.39%
ROIC(3y)N/A
ROIC(5y)N/A
IFRX Yearly ROA, ROE, ROICIFRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

IFRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IFRX Yearly Profit, Operating, Gross MarginsIFRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

3

2. Health

2.1 Basic Checks

IFRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
IFRX has more shares outstanding than it did 1 year ago.
IFRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, IFRX has a worse debt to assets ratio.
IFRX Yearly Shares OutstandingIFRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
IFRX Yearly Total Debt VS Total AssetsIFRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

IFRX has an Altman-Z score of -4.21. This is a bad value and indicates that IFRX is not financially healthy and even has some risk of bankruptcy.
IFRX has a Altman-Z score (-4.21) which is in line with its industry peers.
IFRX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
IFRX has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: IFRX outperforms 46.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.21
ROIC/WACCN/A
WACC7.21%
IFRX Yearly LT Debt VS Equity VS FCFIFRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 4.10 indicates that IFRX has no problem at all paying its short term obligations.
The Current ratio of IFRX (4.10) is comparable to the rest of the industry.
IFRX has a Quick Ratio of 3.78. This indicates that IFRX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.78, IFRX perfoms like the industry average, outperforming 46.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 3.78
IFRX Yearly Current Assets VS Current LiabilitesIFRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

IFRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.11%, which is quite good.
Looking at the last year, IFRX shows a very strong growth in Revenue. The Revenue has grown by 54.69%.
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)54.69%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%550%

3.2 Future

The Earnings Per Share is expected to grow by 8.79% on average over the next years. This is quite good.
IFRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 88.39% yearly.
EPS Next Y15%
EPS Next 2Y11.08%
EPS Next 3Y4.64%
EPS Next 5Y8.79%
Revenue Next Year-76.66%
Revenue Next 2Y83.09%
Revenue Next 3Y110.67%
Revenue Next 5Y88.39%

3.3 Evolution

IFRX Yearly Revenue VS EstimatesIFRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
IFRX Yearly EPS VS EstimatesIFRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IFRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IFRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IFRX Price Earnings VS Forward Price EarningsIFRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IFRX Per share dataIFRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.08%
EPS Next 3Y4.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IFRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INFLARX NV

NASDAQ:IFRX (9/11/2025, 8:00:01 PM)

Premarket: 1.49 +0.02 (+1.36%)

1.47

-0.11 (-6.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners26.33%
Inst Owner Change-3.42%
Ins Owners6.43%
Ins Owner ChangeN/A
Market Cap99.59M
Analysts84.29
Price Target4.52 (207.48%)
Short Float %1.43%
Short Ratio2.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.72%
Min EPS beat(2)-11.29%
Max EPS beat(2)30.73%
EPS beat(4)2
Avg EPS beat(4)17.61%
Min EPS beat(4)-17.65%
Max EPS beat(4)68.63%
EPS beat(8)4
Avg EPS beat(8)9.71%
EPS beat(12)8
Avg EPS beat(12)18.17%
EPS beat(16)11
Avg EPS beat(16)18.5%
Revenue beat(2)0
Avg Revenue beat(2)-61.89%
Min Revenue beat(2)-100%
Max Revenue beat(2)-23.79%
Revenue beat(4)1
Avg Revenue beat(4)-43.99%
Min Revenue beat(4)-100.86%
Max Revenue beat(4)48.71%
Revenue beat(8)1
Avg Revenue beat(8)-70.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.33%
PT rev (3m)-16.22%
EPS NQ rev (1m)5.94%
EPS NQ rev (3m)40.14%
EPS NY rev (1m)1.74%
EPS NY rev (3m)14.69%
Revenue NQ rev (1m)-2.48%
Revenue NQ rev (3m)-63.93%
Revenue NY rev (1m)-7.01%
Revenue NY rev (3m)-57.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 522.25
P/FCF N/A
P/OCF N/A
P/B 1.49
P/tB 1.5
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0
BVpS0.98
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.67%
ROE -79.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.63%
ROA(5y)-39.97%
ROE(3y)-49.99%
ROE(5y)-47.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.82%
Cap/Sales 27.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.1
Quick Ratio 3.78
Altman-Z -4.21
F-Score3
WACC7.21%
ROIC/WACCN/A
Cap/Depr(3y)17.06%
Cap/Depr(5y)14.01%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y15%
EPS Next 2Y11.08%
EPS Next 3Y4.64%
EPS Next 5Y8.79%
Revenue 1Y (TTM)54.69%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%550%
Revenue Next Year-76.66%
Revenue Next 2Y83.09%
Revenue Next 3Y110.67%
Revenue Next 5Y88.39%
EBIT growth 1Y2.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year97.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.41%
OCF growth 3YN/A
OCF growth 5YN/A